Outcome of children with primary resistant or relapsed non-hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the austrian cooperative study group

Pediatric Blood and Cancer

Volumn 44, Issue 1, 2005, Pages 70-76

  Attarbaschi, Andishe ^a   Dworzak, Michael ^a   Steiner, Manuel ^a   Urban, Christian ^b   Fink, Franz Martin ^c   Reiter, Alfred ^d   Gadner, Helmut ^a   Mann, Georg ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Mature B cell leukemia (B ALL); Non Hodgkin lymphoma (NHL); Outcome; Relapse; Resistant disease

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; VINCRISTINE;

ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; DISEASE RESISTANCE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; LEUKEMIA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 10044263449     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20121     Document Type: Article

References (34)

1. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294-3306.
2. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 2000;95:416-421.
3. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001;97:3699-3706.
4. Patte C, Auperin A, Michon J, et al. The Société Francaise d'Oncologie Pédiatrique LMB89 protocol: Highly effective multi-agent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
5. Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Hematol 2001;112:965-968.
6. Philip T, Hartmann O, Pinkerton R, et al. Curability of relapsed childhood B-cell non-Hodgkin lymphoma after intensive first line therapy: A report from the Société Francaise d'Oncologie Pédiatrique. Blood 1993;81:2003-2006.
7. Patte C, Frappaz D, Bertrand Y, et al. Outcome of relapsed childhood B-cell lymphoma (BCL) after intensive first line treatment (Tt): The experience of the French Society of Pediatric Oncology (SFOP) in the LMB89 protocol. Med Pediatr Oncol 1999;abstract:218.
8. Bergeron C, Patte C, Gentet JC, et al. "VANDA" as treatment for lymphoblastic lymphoma (LL) relapses in children treated by SFOP LMT 89 protocol. Med Pediatr Oncol 1999;abstract:217.
9. Gentet JC, Patte C, Quintana E, et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin lymphoma: A study of the French Society of Pediatric Oncology. J Clin Oncol 1990;8:661-665.
10. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology. Ann Oncol 2000;11:53-58.
11. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Münster Group studies. J Clin Oncol 1994;12:899-908.
12. Ladenstein R, Pearce R, Hartmann O, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt lymphoma: A report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997;90:2921-2930.
13. Levine JE, Harris RE, Loberiza FR, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003;101:2476-2482.
14. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003;31:667-678.
15. Sandlund JT, Bowman L, Heslop HE, et al. Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy 2002;4:253-258.
16. Bureo E, Ortega JJ, Munoz A, et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995;15:353-359.
17. Fanin R, Ruiz de Elvira MC, Sperotto A, et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: Analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23:437-442.
18. Uckun FM, Reaman GH. Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 1995;18:195-201.
19. Berdeja JG. Immunotherapy of lymphoma: Update and review of the literature. Curr Opin Oncol 2003;15:363-370.
20. Attarbaschi A, Mann G, Dworzak M, et al. Malignant non-Hodgkin lymphoma of childhood and adolescence in Austria - therapy results between 1986 and 2000. Wien Klin Wochenschr 2002;114:978-986.
21. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol 1995;13:359-372.
22. Borgmann A, Hartmann R, Schmid H, et al. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: A comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group. Bone Marrow Transplant 1995;15:515-521.
23. Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 2000;35:20-27.
24. Mussolin L, Basso K, Pillon M, et al. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt lymphomas by long-distance polymerase chain reaction for t(8:14)(q24;q32). Leukemia 2003;17:585-589.
25. Cave H, Suciu S, Preudhomme C, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Results of EORTC studies 58881 and 58951. Blood 2004;103:442-450.
26. Sheperd SF, A'Hern RP, Pinkerton CR on behalf of the United Kingdom Children's Cancer Study group (UKCCSG). Childhood T-cell lymphoblastic lymphoma - does early resolution of mediastinal mass predict for final outcome? Br J Cancer 1995;72:752-756.
27. Israel O, Front D, Lam M, et al. Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer 1988;61:2439-2443.
28. Bangerter M, Kotzerke J, Griesshammer M, et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804.
29. Zijlstra JM, Hoekstra OS, Raijmakers PG, et al. 18-FDG positron emission tomography versus 67-Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin lymphoma. Br J Haematol 2003;123:454-462.
30. Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin lymphoma. J Clin Oncol 1988;6:1118-1124.
31. Grigg AP, Seymour JF. Graft versus Burkitt lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma 2002;43:889-892.
32. Turturro F, Arnold MD, Frist AY, et al. Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res 2002;8:240-245.
33. Creutzig U, Berthold F, Boos J, et al. Improved treatment results in children with AML: Results of study AML-BFM 93. Klin Pädiatr 2001;213:175-185.
34. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.